Related by context. All words. (Click for frequent words.) 69 mmHg p = 68 % CI #.#-#.# [001] 67 mg p = 67 statistically significant p = 67 mL/min/#.# m 2 67 Folfox 67 infliximab monotherapy 66 statistical significance p 66 Hazard Ratio = 65 TAXUS p value 65 plus prednisone prednisolone 65 XIENCE V vs. 64 P ≤ 64 prednisone prednisolone plus 64 FluCAM arm 64 mU liter 64 oxycodone CR 64 achieved ACR# 64 elevated transaminases 64 hyperphenylalaninemia HPA due 64 recurrent glioblastoma multiforme 64 myelodysplastic myeloproliferative diseases 64 BMS p = 63 ng dL 63 underwent prostate biopsy 63 serum phosphorous 63 pT3 63 relapsed MM 63 x ULN 63 elevated ALT 63 urinary N telopeptide 63 statistically significant p 63 pmol liter 62 microbiologically evaluable 62 splenectomized 62 mild renal insufficiency 62 % Confidence Interval 62 aspartate aminotransferase 62 CALGB # [002] 62 mg TID 62 achieved statistical significance 62 g dl 62 g dL 62 hypophosphatemia 62 #mg BID [001] 62 low dose Iluvien 62 confidence interval #.#-#.# 62 placebo dexamethasone 62 alanine aminotransferase 62 #.#/#.# mmHg [001] 62 ug dose 62 hematopoietic cancers 62 Non inferiority 62 specific antigen PSA 62 advanced adenomas 61 stage IIIb IV 61 NATRECOR R 61 non splenectomized 61 PSA nadir 61 PLX STROKE targeting 61 underwent surgical resection 61 metastatic GIST 61 smoldering multiple myeloma 61 baseline HbA1c 61 INSPIRE Trial Phase III 61 baseline Hb 61 Pharmacokinetic parameters 61 Zometa hazard 61 comparator arm 61 Mg Usa 61 placebo p = 61 genotype 1b 61 deep venous thromboses 61 ng dl 61 glycosylated hemoglobin HbA1c 61 biochemical relapse 61 nonsignificant difference 61 % CI #.#-#.# [003] 61 #q# deletion syndrome 61 calculated creatinine clearance 61 Fasting blood glucose 61 haematologic 61 glycated hemoglobin HbA1c 61 μmol L 61 mitoxantrone plus 61 mmol l 61 -#.# log# copies mL 61 IMiDs ® compound 61 annualized relapse 61 baseline serum creatinine 61 nondiabetic patients 61 mcg QD 61 μg L 61 8mg/kg 61 lopinavir r arm 61 mg Androxal 61 HBeAg negative patients 61 dalteparin 61 morphometric vertebral fractures 60 abnormal p# biomarker 60 #.#ng/ml 60 QTcF 60 #ng/ml 60 mg kg dose 60 mU L 60 -#.# mg dL [002] 60 mIU L 60 oral antidiabetes 60 mcg Albuferon 60 CIN2 + 60 p = NS 60 MDS MPD 60 ritonavir boosted atazanavir 60 MGd 60 overt nephropathy 60 postintervention 60 recombinant PSMA vaccine 60 locoregional recurrence 60 pmol L 60 ULORIC 60 CTAP# Capsules 60 serum estradiol 60 linaclotide treated 60 recurrent DVT 60 log# copies mL 60 #.#mg/dL 60 DAS# CRP 60 unfractionated heparin UFH 60 Engerix B 60 antiretroviral naïve 60 HOMA IR 60 Intravitreal 60 lactate dehydrogenase 60 μg mL 60 naïve HCV 60 decompensated liver disease 60 hepatorenal syndrome 60 ACTEMRA TM 60 NOXAFIL Oral Suspension 60 Ribavirin causes 60 titrated glipizide 60 plus prednisone 60 ARCALYST ® 60 colorectal adenoma 60 mycophenolic acid 60 alanine transaminase ALT 60 creatinine ratio 60 log# IU mL 60 LH FSH 60 refractory NSCLC 60 microgram kg 60 humanized interleukin 6 60 serum ALT 60 hemoglobin Hb 60 mg/m2 dose 60 glycated hemoglobin levels 59 Naive Patients 59 alanine aminotransferase ALT 59 metastatic pancreatic 59 papillary renal cell carcinoma 59 evaluating tivozanib 59 obstructive coronary artery 59 hemoglobin A1c HbA1c 59 AST ALT 59 abacavir lamivudine 59 nanograms milliliter 59 #mg/day [002] 59 KRAS mutations occur 59 lactate dehydrogenase LDH 59 mL/min/#.# m2 59 histologic subtype 59 genitourinary GU 59 REMICADE monotherapy 59 genotypic resistance 59 completely resected 59 leukopenia 59 galiximab 59 Hazard Ratio HR 59 cyclophosphamide methotrexate 59 PROCTOCORT ® Suppository Hydrocortisone 59 tirofiban 59 candesartan cilexetil 59 p# biomarker 59 STRIDE PD 59 squamous intraepithelial lesions 59 Solid Tumors criteria 59 bone marrow reticulin deposition 59 Known hypersensitivity 59 mIU ml 59 iniparib BSI 59 ® lenalidomide 59 Xalatan R 59 gm dl 59 CYT# potent vascular disrupting 59 baseline A1C 59 Teriflunomide 59 Mg Uk 59 mg BID dose 59 placebo p 59 undetectable HBV DNA 59 mm Hg diastolic 59 Secondary endpoints include 59 nucleoside naive 59 Hazard Ratio 59 mcg albinterferon alfa 2b 59 TNF antagonist 59 bovine thrombin 59 -#.# log# 59 nmol liter 59 lymphocytosis 59 cGy 59 preintervention 59 advanced adenoma 59 FUSILEV enhances 59 baseline serum bilirubin 59 mCi 59 CYPHER Stent 59 lispro 59 nicardipine 59 highest tertile 59 mmHg diastolic 59 refractory chronic lymphocytic 59 microbiological eradication 59 Cystatin C 59 baseline neutrophil counts 59 urine albumin 59 tetraborate fusion 59 quetiapine risperidone 59 underwent CABG 59 serum selenium 59 Ishak fibrosis score 59 Carotid Revascularization Endarterectomy vs. 59 bronchoalveolar lavage 59 ritonavir boosted 59 NNT = 59 HER2 expression 59 somatostatin analog 59 underwent resection 59 sirolimus stent 59 ADCS CGIC 59 HbA 1c levels 59 antibody MAb 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 HBeAg seroconversion 59 undergone radical prostatectomy 59 hematological parameters 59 q#h 59 glomerular filtration 59 onset diabetes mellitus 59 dehydroepiandrosterone sulfate 59 deCODE AF TM 58 metastatic malignant 58 lung esophageal 58 hyperinsulinemic euglycemic clamp 58 mean baseline A1C 58 endoscopic remission 58 undetectable viral 58 bendamustine ifosfamide 58 5 Fluorouracil 58 mg QD 58 SGPT 58 Acetate Rectal Suppositories 58 hydroxyvitamin D levels 58 azilsartan medoxomil 58 intima media thickness 58 atazanavir ritonavir 58 pegylated interferon alpha 58 IOP lowering 58 REVIVE Diabetes 58 placebo PBO 58 CrCl 58 -#.# p = 58 efavirenz EFV 58 PREZISTA r 58 postmenopausal osteoporotic women 58 unresectable tumors 58 postprocedure 58 Myelosuppression 58 IFN alfa 58 certolizumab 58 umol L 58 PASI scores 58 mcg kg min 58 mcg mL 58 p = .# [002] 58 Subgroup analysis 58 cilostazol 58 Hormone receptor 58 reduce serum phosphate 58 bone marrow reticulin 58 lumbar spine BMD 58 dizziness nausea diarrhea 58 dexamethasone Decadron 58 RLAI 58 leukocyte count 58 plus OBT 58 Amgen Neulasta R 58 aspartate aminotransferase AST 58 ug kg 58 HGPIN 58 gadobutrol 58 thyroglobulin 58 mCi kg 58 pharmacologic stress 58 aerosolized AAT 58 definite stent thrombosis 58 corticosteroid dose 58 pooled comparator 58 μg dose 58 receiving XGEVA 58 pg ml 58 MAGE A3 ASCI 58 pg mL 58 serum leptin 58 VELCADE melphalan 58 bronchial hyperresponsiveness 58 RECIST Response Evaluation Criteria 58 Severity MSCS score 58 #mg ATC 58 ng mL 58 treatment naïve genotype 58 NMIBC 58 cisplatin vinorelbine 58 doxorubicin cyclophosphamide 58 T1c 58 registrational Phase 58 HCV RESPOND 2 58 EXJADE 58 oral antidiabetic medication 58 venlafaxine XR 58 CC genotype 58 ovarian carcinoma 58 mcg linaclotide 58 lopinavir r 58 CYP#A# substrate 58 aspirin clopidogrel 58 3mg/kg 58 Primary endpoints 58 dacarbazine DTIC 58 FOLFOX4 58 LungAlert TM 58 ACR# ACR# 58 GH deficiency 58 CIMZIA TM certolizumab pegol 58 Serum creatinine 58 EpCAM expression 58 hyperlipemia 58 sitaxsentan 58 detectable HCV RNA 58 -#.# ± [001] 58 antidepressants fluoxetine 58 preoperative PSA 58 exocrine pancreatic insufficiency EPI 58 PREZISTA r arm 58 intraobserver 58 GOUT 58 ALT elevation 58 4mg/kg 58 CCyR 58 CLL SLL 58 resectable pancreatic cancer 58 mcg dL 58 Aflibercept 58 hip BMD 58 prospectively stratified 58 P = .# 58 clinicopathological features 58 CI #.#-#.# [002] 58 hemostatic efficacy 58 mcg BID 58 saline placebo 58 desvenlafaxine succinate 58 mITT population 58 CIMZIA TM 58 hemodynamically unstable 58 Pharmacokinetics PK 57 N telopeptide 57 highly emetogenic 57 #mg/day [001] 57 mmol L 57 pretest probability 57 receiving Vectibix monotherapy 57 irbesartan 57 μg g 57 CsA 57 ertapenem 57 trastuzumab Herceptin R 57 arterial thromboembolic events 57 Viread Emtriva Sustiva 57 sUA 57 radiotherapy RT 57 seropositivity 57 mcg kg REBETOL 57 binary restenosis 57 nonmetastatic 57 Skin sterol 57 Tasigna prolongs 57 receiving INTRON 57 prolonged QT interval 57 underwent percutaneous coronary 57 serum aminotransferase levels 57 ARB telmisartan 57 microalbumin test 57 colorectal carcinoma 57 HBV infections 57 sensitivity specificity 57 coronary stenosis 57 aminotransferase levels 57 Oral Fingolimod 57 mg Lucentis 57 primary hypercholesterolemia 57 mIU mL 57 detectable BPA 57 include ColorectAlert TM 57 posaconazole 57 mg q#h 57 % CI #.#-#.# [005] 57 Am J Cardiol 57 serum GGT 57 aplastic anemia AA 57 neurologic progression 57 grade cervical intraepithelial 57 Endometrial 57 epoetin alpha 57 NCCTG N# 57 seropositive 57 basal bolus therapy 57 mg qd 57 prednisone prednisolone 57 advanced metastatic renal 57 % CI #.#-#.# [008] 57 discontinued Viread 57 neutropenic sepsis 57 oxycodone IR 57 ATACAND 57 Peg IFN 57 Index CDAI 57 budesonide pMDI 57 AA Amyloidosis 57 baseline LDH 57 retinal vein occlusion induced 57 pCR 57 #mg q8h 57 placebo fluoxetine 57 severe renal impairment 57 mineral density BMD 57 aPTT 57 LDL triglycerides 57 nadroparin 57 hepatic enzyme 57 Heterozygous Familial Hypercholesterolemia 57 Pred Forte 57 metastatic colorectal 57 EOquin TM phase 57 CTEPH 57 protein excretion 57 workhorse lesions 57 HNSCC 57 urinary cortisol 57 chemoradiation therapy 57 mm ³ 57 malignancy HCM 57 ancrod 57 receiving highly emetogenic 57 confidence interval CI 57 ug mL 57 aldosterone antagonist 57 anti JCV antibodies 57 prostate carcinoma 57 substantially excreted 57 underwent coronary angiography 57 reinfarction 57 SUVmax 57 microgram mcg 57 retrospective cohort 57 mEq L 57 ductal carcinomas 57 undergone splenectomy 57 liver decompensation 57 urate lowering therapy 57 tipranavir r 57 mmol kg 57 hormone receptor negative 57 Basso Jan Ullrich 57 #mg QD [002] 57 alpha1 antitrypsin deficiency 57 alfuzosin 57 folic acid takers 57 Operative mortality 57 Vancocin p = 57 novel VDA molecule 57 neutrophil counts 57 deCODE ProstateCancer TM 57 plus methotrexate 57 EURIDIS 57 serum phosphate 57 transferrin saturation 57 hydroxymethyl coenzyme 57 anemia hemoglobin 57 Zorbtive TM 57 humanised monoclonal antibody 57 echocardiographic parameters 57 BENICAR HCT 57 nmol 57 #mg QD [001] 57 gastrointestinal stromal 57 dose escalation clinical 57 transaminase elevations 57 5 FU leucovorin 57 VaD 57 Relapsed Refractory Multiple Myeloma 57 piperacillin tazobactam 57 -#.# ± [002] 57 Xelox 57 5-FU/LV 57 p = #.# [003] 57 serum PSA 57 INCB# [003] 57 PREZISTA ritonavir 57 mutated K ras 57 LAB CGRP 57 serum urate levels 57 vapreotide acetate 57 barbiturates benzodiazepines 57 Flu Cy 57 homocysteine concentrations 57 specific alkaline phosphatase 57 histological subtype 57 alfa 2a 57 μg dl 57 amprenavir 57 PEGylated anti 57 surgically resected 57 unstable angina pectoris 57 intravesical therapy 57 HbA1C 57 abnormal p# 57 cervical intraepithelial neoplasia 57 #mg BID [003] 57 intravenous bolus 57 drotrecogin alfa activated 57 plus dexamethasone 57 dose cohort 57 Kinoid 57 maternal serum 56 Cancer Incidence Mortality 56 esophageal carcinoma 56 glulisine 56 HER2 overexpression 56 IR Cysteamine 56 Soft Tissue Sarcoma 56 recurrent VTE 56 #mmHg [001] 56 tumors GIST 56 β blocker 56 ARCOXIA 56 standard chemotherapy regimen 56 BRAF gene mutations 56 mucosal healing 56 Brief Psychiatric 56 BCG vaccinated 56 multivariable adjusted 56 dyslipidemia abnormal 56 mg ustekinumab 56 demonstrated antitumor activity 56 neutrophil count 56 statin monotherapy 56 bioavailable testosterone 56 CI -#.# 56 receiving ISENTRESS 56 NSABP B 56 IV NSCLC 56 Pharmacogenetic 56 psoriatic arthritis PsA 56 GRNOPC1 contains 56 lowest tertile 56 anaphylactic reactions bronchospasm 56 PRADAXA #mg 56 acetonide FA 56 hsCRP levels 56 q8h 56 reactogenicity 56 Prostate specific antigen 56 catheter occlusion 56 Response Evaluation Criteria 56 ALT normalization 56 Interrater reliability 56 CR CRu 56 serum prostate 56 refractory cutaneous T 56 relapsing remitting MS RRMS 56 cromolyn sodium 56 ABCB1 56 Randomized Phase II 56 CI = 56 Lucentis monotherapy 56 Median progression 56 Relapsing Remitting Multiple Sclerosis 56 peritumoral brain edema 56 NHANES III 56 gestational hypertension 56 F FDG PET 56 μg l 56 severe neutropenia 56 μg kg 56 invasive lobular 56 rapid virologic response 56 papillary carcinoma 56 Techni lab 56 ® darbepoetin alfa 56 HBeAg negative 56 CHAMPION PCI 56 BARACLUDE ® 56 hematologic toxicity 56 nondiabetics 56 FOLFIRI alone 56 C telopeptide 56 EDEMA3 trial 56 System IPSS 56 Val HeFT 56 Cervista HPV HR 56 MELD scores 56 plasma pharmacokinetics 56 histologically confirmed 56 lamivudine refractory patients 56 coinfected patients 56 Gynecologic Oncology Group 56 Velcade bortezomib 56 erythrocyte sedimentation rate 56 PSADT 56 minimally symptomatic 56 cisplatin gemcitabine 56 achieved PASI 56 latent tuberculosis infection 56 controlled dose escalation 56 biopsy Gleason 56 sulfonylurea metformin 56 atorvastatin #mg 56 Peginterferon 56 BRIM2 56 aminotransferases 56 -#.# mg dL [001] 56 endometrial thickness 56 serum uric acid 56 #mg dose [002] 56 bacterial prostatitis 56 banned stimulant carphedon 56 invasive lobular carcinoma 56 moderate renal impairment 56 symptomatic BPH 56 glomerular filtration rate 56 phase IIb study 56 receiving prophylactic anticoagulation 56 #rd Annual CTRC 56 lymphocyte count 56 serum potassium 56 recurrent metastatic 56 serum calcium levels 56 Hb A1C 56 xanthine oxidase inhibitor 56 antibody titer 56 elotuzumab 56 Vidaza ® 56 subcutaneous enoxaparin 56 #Gy 56 mRCC 56 noninferior 56 carotid IMT 56 Natalizumab 56 gastrointestinal perforation 56 activated partial thromboplastin 56 Follicular Lymphoma 56 neuropathy sensory 56 Arch Intern Med 56 pT2 56 initiating antiretroviral therapy 56 sorafenib tablets 56 â ‰ ¥ 56 oral allopurinol 56 cTnI 56 cinacalcet HCl 56 Myocardial Infarction Study 56 achieved CCyR 56 hypogonadal 56 mcg kg 56 null responder HCV 56 sustained virological response 56 μg ml 56 % CI #.#-#.# [007] 56 Fasting plasma glucose 56 anti HBs 56 CK MB 56 basiliximab 56 tryptase 56 EMPHASIS HF trial 56 serum testosterone 56 % CI #.#-#.# [004] 56 RECORD1 56 Contrave# 56 severe exacerbations 56 Doxil ® 56 allogeneic hematopoietic stem cell 56 serum lipid levels 56 EEG abnormalities 56 mg + GLY 56 systolic dysfunction 56 % CI #.#-#.# [006] 56 euthyroid 56 distant metastasis 56 TAXUS Express Stent 56 HBsAg positive 56 serum triglyceride levels 56 TDF FTC 56 Plicera TM 56 arterial oxygen saturation 56 intravascular hemolysis 56 noninvasive outpatient 56 creatinine clearance 56 metastatic HRPC 56 prostate cancer CaP 56 ara C 56 APTIVUS r 56 BUPHENYL 56 treatment naive genotype 56 QT QTc 56 mineral density 56 noninferiority 56 albumin excretion rate 56 treats paroxysmal nocturnal 56 human chorionic gonadotropin hCG 56 Achieves Primary Endpoint 56 dosing cohort 56 hemodynamically significant 56 mapatumumab 56 serum antibody 56 doxorubicin docetaxel 56 patients undergoing CABG 56 elevated LDL cholesterol 56 peripheral blood mononuclear 56 NMP# protein 56 liver histology 56 Papillary 56 culture supernatants 56 HIV HCV coinfected 56 interleukin IL -# 56 aminotransferase ALT 56 HCV antibody 56 NATRECOR ® 56 ptau 56 urine cytology 56 velafermin 56 HBeAg 56 coronary revascularisation 56 ug ml 56 XIENCE V PROMUS Stent 56 thromboembolic events 56 undergoing coronary angiography 56 Lymphocytic 55 CIMZIA ™ 55 multiple myeloma MM 55 nadolol 55 pelvic malignancies 55 conjugated equine estrogen 55 dose melphalan 55 oral Hycamtin 55 clodronate 55 HbA1C levels 55 intact parathyroid hormone 55 Telik logo TELINTRA 55 methylmalonic acid 55 Group RTOG 55 fosamprenavir 55 Psoriasis Area 55 μg liter 55 serum IGF 55 folate vitamin B6 55 BCIRG 55 smoldering myeloma 55 urate lowering 55 sonographically guided 55 cancer mCRC 55 clinico pathological 55 Adenomas 55 Inhibin B 55 oral diclofenac 55 fasting plasma 55 MBq 55 rFSH 55 recurrent UTI 55 ritonavir boosted lopinavir 55 Skin prick 55 crizotinib PF # 55 ropivacaine 55 adalimumab Humira 55 non valvular atrial 55 ELACYT 55 transaminase 55 artificial arteriovenous dialysis 55 plus COPEGUS 55 LEXIVA r 55 inotropic agents 55 pancreatic prostate 55 EGFR TKI 55 erythema nodosum 55 fasting triglyceride levels 55 adjunctive ABILIFY 55 Plasma concentrations 55 #.#/#.# mm Hg [003] 55 teriflunomide 55 deletion 5q 55 symptomatic carotid stenosis 55 hypercholesterolaemia 55 F2 isoprostanes 55 element ICP analysis 55 HCV SPRINT 55 Peginterferon Alfa 2a 55 mm Hg systolic 55 5-fluorouracil/leucovorin 55 fasting serum 55 HBeAg positive patients 55 cEVR 55 adjunctive placebo 55 tipranavir ritonavir 55 Atypical Hemolytic Uremic Syndrome 55 PEG IFN 55 situ LCIS 55 MADRS score 55 Montgomery Åsberg Depression 55 thromboembolic 55 stage IIIB 55 ASCUS 55 MCyR 55 carboplatin paclitaxel 55 TEAEs 55 fasting plasma glucose FPG 55 #mg doses [002] 55 silent ischemia 55 sunitinib Sutent 55 BRIM3 55 Non Alcoholic Steatohepatitis 55 invasive carcinomas 55 TURBT 55 ABSORB trial 55 hematological cancers notably 55 LAB GHRH 55 prospectively enrolled 55 TRAIL R1 55 cardiovascular hospitalizations 55 mecasermin rDNA origin 55 Prognostic significance 55 pretreatment serum 55 cTnT 55 Immunohistochemical staining 55 parous women 55 colon rectal 55 serum BDNF 55 timolol 55 mg tid 55 serum urate 55 posttreatment 55 docetaxel chemotherapy 55 assessing T DM1 55 receiving VICTRELIS 55 transcranial Doppler ultrasound 55 Histopathological 55 active comparator 55 forodesine 55 invasive ductal 55 troponin T 55 achieved sustained virologic 55 D dimer 55 Median survival 55 humanized therapeutic 55 heparanase 55 noncardiovascular mortality 55 metformin monotherapy 55 grade cervical dysplasia 55 glycated hemoglobin 55 telaprevir dosed 55 R entecavir 55 RhuDex ™ 55 approved incretin mimetic 55 Crohn Disease Activity 55 icatibant 55 Erythropoietic therapies may 55 min -1 55 adjuvant cisplatin 55 Viread Emtriva 55 median CD4 55 6 phosphate dehydrogenase 55 convulsive disorders 55 CANCIDAS 55 NSAID associated 55 revascularizations 55 adenoma recurrence 55 squamous histology 55 visit www.genenews.com 55 dose escalation phase 55 pegIFN 55 confirmed CCyR 55 CIN3 55 docetaxel Taxotere R 55 endometrial hyperplasia 55 cis retinoic acid 55 complete cytogenetic response 55 dapagliflozin plus 55 GSTP1 55 histone deacetylase HDAC inhibitor 55 glargine 55 diuretics beta blockers 55 metoprolol tartrate 55 postoperative mortality 55 Cream USP 1 55 corrected QT interval 55 FDG uptake 55 thyrotropin levels 55 Postoperative complications 55 laboratory abnormalities 55 log# 55 tPSA 55 Mean Symptom Complex 55 creatinine levels 55 weekly intravenous infusions 55 pain palliation 55 vinca alkaloid 55 resected pancreatic cancer 55 Italians Riccardo Ricco 55 chronic thromboembolic pulmonary 55 tumor progression TTP 55 irinotecan cisplatin 55 resistant hormone refractory 55 Fludara 55 attain statistical significance 55 autoimmune thyroid 55 radiolabeled TM# 55 plasma triglycerides 55 Prospective Randomized 55 Clusterin 55 Amrubicin 55 Hepsera adefovir dipivoxil 55 Recombinant EPO 55 DAS# scores 55 renal insufficiency 55 mso footer margin 55 CML CP 55 metformin hydrochloride 55 CI #.#-#.# [001] 55 CP CPPS 55 kilogram mg kg 55 LymphoStat B belimumab 55 Adjuvant chemotherapy 55 postoperative chemotherapy 55 Adjuvant Treatment 55 Castration Resistant Prostate Cancer 55 Group B CALGB 55 plasma uric acid 55 induced anemia 55 SSc 55 LDH lactate dehydrogenase 55 ipsilateral breast 55 mmol L. 55 inhibit platelet function 55 index assay IVDMIA 55 renal biopsy 55 Platelet counts 55 nitroprusside 55 interferon gamma 1b 55 coagulation abnormalities 55 abnormal cytology 55 left ventricular systolic 55 doripenem 55 ZOLINZA 55 multicenter randomized controlled 55 diameter stenosis 55 tumor histology 55 Occlusive Disease 55 cardiac troponin T 55 HER2 positive metastatic breast 55 plus 5-FU/LV 55 hemoglobin concentrations 55 inconclusive Pap 55 rheumatoid factor 55 postoperative complication 55 mmHg systolic 55 nonfatal stroke 55 transrectal ultrasound guided 55 inotropic 55 EGFR mutation positive 55 pyrimidine nucleoside analog 55 pegylated interferon alfa 2b 55 #mg #mg #mg [003] 55 REYATAZ r arm 55 μg doses 55 visilizumab 55 concomitant cardiac 55 postoperative morbidity 55 concomitant medications 55 adefovir treated 55 triglyceride concentrations